Preoperative endocrine therapy for breast cancer

Endocrine-Related Cancer

Volumn 7, Issue 3, 2000, Pages 131-141

  Cheung, K L ^a   Howell, A ^a   Robertson, J F R ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; CATHEPSIN D; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FORMESTANE; FULVESTRANT; GOSERELIN; KI 67 ANTIGEN; LETROZOLE; LEUPRORELIN; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; PREDNISOLONE; PROTEIN PS2; TAMOXIFEN; VINCRISTINE;

BREAST CANCER; CANCER HORMONE THERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; MASTECTOMY; PEROPERATIVE CARE; PHASE 2 CLINICAL TRIAL; PROTEIN EXPRESSION; REVIEW;

EID: 0033790870     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0070131     Document Type: Review

References (55)

1. A 10-year experience of tamoxifen as primary treatment of breast cancer in 100 elderly and frail patients
2. Tamoxifen as primary treatment of breast cancer in elderly or frail patients: A practical management
3. Response to endocrine manipulation and oestrogen receptor concentration in large operable breast cancer
4. Primary systemic therapy for operable breast cancer
5. Expression of ras, p21, p53 and c-erbB2 in advanced breast cancer and response to first line hormonal therapy
6. Effects of short-term preoperative tamoxifen on steroid receptor and Ki67 expression in primary breast cancer: An immunocytochemical study
7. Breast cancer in elderly women: A Cancer Research Campaign trial comparing treatment with tamoxifen and optimal surgery with tamoxifen alone. The Elderly Breast Cancer Working Party
8. Should tamoxifen be a primary treatment choice for elderly breast cancer patients with locoregional disease?
9. Primary treatment of breast cancer in elderly women with tamoxifen
10. Primary systemic therapy for operable breast cancer - Year survival data after chemotherapy and hormone therapy
11. Tamoxifen as primary treatment of breast cancer in elderly patients
12. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer
13. Lessons from the use of aromatase inhibitors in the neoadjuvant setting
14. Efficacy of anastrozole as neoadjuvant therapy in postmenopausal women with large operable breast cancers: Reductions in tumour volume
15. Tamoxifen for early breast cancer: An overview of the randomised trials
16. Comparable effect of ovarian ablation and CMF in premenopausal hormone receptor positive chemotherapy breast cancer patients
17. Clinical applications of new aromatase inhibitors
18. Preoperative chemotherapy: A model for studying the biology and therapy of primary breast cancer
19. Presence of a growth stimulating factor in serum following primary tumour removal in mice
20. Effect of local or systemic treatment prior to primary tumour removal on the production and response to a serum growth stimulating factor in mice
21. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18
22. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer
23. A human tumour model
24. Tamoxifen as sole therapy for primary breast cancer in the elderly patient
25. Indications for primary tamoxifen therapy in elderly women with breast cancer
26. Prospective randomised trial of tamoxifen versus surgery in elderly patients with breast cancer
27. Randomised trial chemotherapy versus endocrine therapy in patients presenting with locally advanced breast cancer (a pilot study)
28. Assessment of the effect of pretreatment with neoadjuvant therapy on primary breast cancer
29. A mathematical model for relating the drag sensitivity of tumours to their spontaneous mutation rate
30. Assessment of response to therapy in advanced breast cancer
31. Treatment of early localized breast cancer in elderly patients by tamoxifen
32. The primary use of endocrine therapies
33. Comparison of adjuvant therapy with tamoxifen and goserelin vs CMF in premenopausal stage I and II hormone-responsive breast cancer patients: Four-year results of Austrian Breast Cancer Study Group (ABCSG) Trial 5
34. Breast carcinoma: Measurement of tumour response to primary medical therapy with colour Doppler flow imaging
35. Long-term follow-up of elderly patients randomised to primary tamoxifen or wedge mastectomy as initial therapy for operable breast cancer
36. Primary medical therapy for operable breast cancer
37. Tamoxifen as an alternative to surgical resection for selected geriatric patients with primary breast cancer
38. Mammography in the assessment of response to medical treatment of large primary breast cancer
39. Tamoxifen or surgery plus tamoxifen as primary treatment for elderly patients with operable breast cancer: The GRETA Trial Group for Research on Endocrine Therapy in the Elderly
40. Tamoxifen alone versus surgery plus tamoxifen for breast cancer of the elderly. Meta-analysis of long term results of the GRETA and CRC trials
41. Epidermal growth factor receptor status associated with failure of primary endocrine therapy in elderly postmenopausal patients with breast cancer
42. Regarding: 'Valero V, Buzdar AU, Hortobagyi GN 1996 Locally advanced breast cancer
43. Randomized trial of chemoendocrine therapy started before and after surgery for treatment of primary breast cancer
44. Tamoxifen as initial sole treatment of localised breast cancer in elderly women: A pilot study
45. Comparison of mastectomy with tamoxifen for treating elderly patients with operable breast cancer
46. A partially-blind, randomised, multicentre study comparing the anti-tumour effects of single doses (50, 125 and 250 mg) of long-acting 'Faslodex' (ICI 182,780) with tamoxifen in postmenopausal women with primary breast cancer prior to surgery
47. Epidermal growth factor receptor status as predictor of early recurrence of and death from breast cancer
48. Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: The Scottish trial
49. Primary (neoadjuvant) medical therapy: Introduction
50. pS2 protein: A marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients
51. Treatment of breast cancer in elderly patients
52. The early results from a randomised study of radiotherapy versus Nolvadex (tamoxifen) as initial treatment for stage IlI breast cancer
53. Locally advanced breast cancer: Long-term results of a randomised trial comparing primary treatment with tamoxifen or radiotherapy in postmenopausal women
54. Locally advanced breast cancer: Early results of a randomised trial of multimodal therapy versus initial hormone therapy
55. Investigation of primary tamoxifen therapy for elderly patients with operable breast cancer